YishengBio
IPOGaithersburg, United States · Founded 2002
- Headquarters
- Gaithersburg, Maryland
- Employees
- 501–1000
- Founded
- 2002
- Business Model
- B2B
- Website
- yishengbio.com
- Last Round
- Series BMar 2021
- Rounds
- 1
About
YishengBio (also known as YS Biopharma) develops vaccines and therapeutic biologics for infectious disease and oncology, with R&D and manufacturing operations spanning China and the United States. Its lead program, a next-generation rabies vaccine, has advanced through Phase 2/3 clinical trials in multiple international markets including the Philippines and UAE. The company went public via a 2022 merger with NASDAQ-listed Summit Healthcare Acquisition Corp, later trading as YS Biopharma (NASDAQ: YS) before further corporate restructuring.
Summary
YishengBio is a Biotech company based in Gaithersburg, United States, founded in 2002. Its most recent funding was a Series B round in Mar 2021. Investors include OrbiMed, Oceanpine Capital and F-Prime Capital.
Funding History
Mar 2023
Sign up to see all 2 rounds
Series B through SPAC Merger — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
China's leading blood products manufacturer
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Specialty pharmaceutical company
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Altos Labs combines academic science and industry development to create medicines that restore ce...
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/yishengbio"><img src="https://indexed.vc/api/badge/company/yishengbio" alt="YishengBio on Indexed.vc" width="260" height="76" /></a>